论文部分内容阅读
目的:检测原发性肝癌患者血浆溶血磷脂酸(lysphosphaticlic acid,LPA)的水平,评价LPA在原发性肝癌诊治中的临床意义。方法:采用生物化学方法检测原发性肝癌患者43例,肝脏良性疾病患者10例及健康志愿者10名的血浆LPA水平,同时测定血清AFP的水平。结果:原发性肝癌患者血浆LPA水平(3.94±0.60)μmol/L明显高于肝脏良性疾病患者(2.68±0.36)μmol/L和健康对照组(2.42±0.35)μmol/L(P<0.05),血浆LPA水平的升高与原发性肝癌浸润和门静脉癌栓等相关。结论:血浆LPA检测为原发性肝癌诊断和预后判断增加了一项潜在的评价指标。
Objective: To detect the level of plasma lysophosphaticlic acid (LPA) in patients with primary liver cancer and evaluate the clinical significance of LPA in the diagnosis and treatment of primary liver cancer. Methods: Plasma LPA levels in 43 patients with primary liver cancer, 10 patients with benign liver diseases and 10 healthy volunteers were detected by biochemical methods. Serum AFP level was also measured. Results: The level of plasma LPA in patients with primary liver cancer was significantly higher than that in benign liver diseases (2.68 ± 0.36 μmol / L vs 2.42 ± 0.35 μmol / L, 3.94 ± 0.60 μmol / L, P <0.05) , Plasma LPA levels and primary hepatocellular carcinoma infiltration and portal vein tumor thrombus and so on. Conclusion: Plasma LPA test adds a potential evaluation index for the diagnosis and prognosis of primary liver cancer.